Back to Search
Start Over
Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders
- Source :
- American Journal of Obstetrics and Gynecology. 226:S1019-S1034
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
-
Abstract
- Preeclampsia is a devastating medical complication of pregnancy that can lead to significant maternal and fetal morbidity and mortality. It is currently believed that there is abnormal placentation in as early as the first trimester in women destined to develop preeclampsia. Although the etiology of the abnormal placentation is being debated, numerous epidemiologic and experimental studies suggest that imbalances in circulating angiogenic factors released from the placenta are responsible for the maternal signs and symptoms of preeclampsia. In particular, circulating levels of soluble fms-like tyrosine kinase 1, an antiangiogenic factor, are markedly increased in women with preeclampsia, whereas free levels of its ligand, placental, growth factor are markedly diminished. Alterations in these angiogenic factors precede the onset of clinical signs of preeclampsia and correlate with disease severity. Recently, the availability of automated assays for the measurement of angiogenic biomarkers in the plasma, serum, and urine has helped investigators worldwide to demonstrate a key role for these factors in the clinical diagnosis and prediction of preeclampsia. Numerous studies have reported that circulating angiogenic biomarkers have a very high negative predictive value to rule out clinical disease among women with suspected preeclampsia. These blood-based biomarkers have provided a valuable tool to clinicians to accelerate the time to clinical diagnosis and minimize maternal adverse outcomes in women with preeclampsia. Angiogenic biomarkers have also been useful to elucidate the pathogenesis of related disorders of abnormal placentation such as intrauterine growth restriction, intrauterine fetal death, twin-to-twin transfusion syndrome, and fetal hydrops. In summary, the discovery and characterization of angiogenic proteins of placental origin have provided clinicians a noninvasive blood-based tool to monitor placental function and health and for early detection of disorders of placentation. Uncovering the mechanisms of altered angiogenic factors in preeclampsia and related disorders of placentation may provide insights into novel preventive and therapeutic options.
- Subjects :
- Vascular Endothelial Growth Factor A
Placenta Diseases
Hydrops Fetalis
Intrauterine growth restriction
Twin-to-twin transfusion syndrome
Bioinformatics
Preeclampsia
chemistry.chemical_compound
Pre-Eclampsia
Pregnancy
Placenta
medicine
Humans
Fetal Death
reproductive and urinary physiology
Bronchopulmonary Dysplasia
Placenta Growth Factor
Fibrin
Vascular Endothelial Growth Factor Receptor-1
Proteinuria
business.industry
Obstetrics and Gynecology
Placentation
Fetofetal Transfusion
Puerperal Disorders
Prognosis
medicine.disease
Up-Regulation
Vascular endothelial growth factor
medicine.anatomical_structure
chemistry
Cardiovascular Diseases
embryonic structures
Female
medicine.symptom
business
Biomarkers
Subjects
Details
- ISSN :
- 00029378
- Volume :
- 226
- Database :
- OpenAIRE
- Journal :
- American Journal of Obstetrics and Gynecology
- Accession number :
- edsair.doi.dedup.....7f13ef7316145763a0fa67d0da536606